Haeggquist & Eck, LLP has commenced an investigation into (“KemPharm”) (NASDAQ: KMPH) to determine whether KemPharm and its Officers and Directors have violated the federal securities laws.
KemPharm is a clinical-stage specialty pharmaceutical company, discovers and develops new proprietary prodrugs in the United States. KemPharm was founded in 2006 and is headquartered in Coralville, Iowa.
On May 5, 2016, KemPharm announced that the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the FDA had reviewed and voted on Apadaz, determining by a vote of 16 to 4 that Apadaz should be approved for its proposed indication of the management of acute pain that requires an opioid, but voted 18 to 2 against inclusion of abuse deterrent labeling for the product.
On this news, KemPharm’s stock fell from a May 5, 2016 price of $15.67 to a May 6, 2016 price of $6.91, a one-day decline of approximately 56%.
What You Can Do
If you purchased shares of KemPharm stock, you may have legal claims against the Company and/or its Officers and Directors. If you wish to discuss this investigation, or have questions about this notice or your legal rights, please contact attorney Amber L. Eck at 619-342-8000, or by email at email@example.com. There is no cost to you.